Today, μ-opioids are prescribed for peripheral pain, but they come with the risk of many toxicities including gastrointestinal issues, sedation, and addiction. The compound of study, referred to as JT09, has shown peripheral pain alleviation with high selectivity of κ-opioid receptors compared to μ- and δ-opioid receptors; this prevents the drug from having any effect on the central nervous system as it cannot cross the blood brain barrier. JT09 has been incorporated into ProNeura rods, subdural implants that continually administers the drug for up to 12 months. This technology may render the need for oral and intravenous administration unnecessary, as well as decrease the number of addictive drugs available to the public. Future directions include pharmacokinetics studies, as well as immunohistochemistry studies to observe the location, action, and relation of κ-opioid receptors (KORs) with myocardial infarction (MI) size and its influence on other antigens.

Second-generation κ-opioid agonist as a peripherally-restricted analgesic

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.